Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis

Shawn G. Kwatra; Gil Yosipovitch; Franz J. Legat; Adam Reich; C. Paul; Dagmar Simon; Luigi Naldi; Charles Lynde; Marjolein de Bruin‐Weller; Walter K. Nahm; Maxwell Sauder; Rola Gharib; S. Barbarot; Jacek C. Szepietowski; Curdin Conrad; Alan B. Fleischer; Vivian Laquer; L. Misery; E. Serra‐Baldrich; Hilde Lapeere; Faiz Ahmad; Zarif K. Jabbar Lopez; Christophe Piketty; Sonja Ständer

doi:10.1056/nejmoa2301333

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Nemolizumab monotherapy significantly reduced the signs and symptoms of prurigo nodularis. (Funded by Galderma; ClinicalTrials.gov number, NCT04501679; EudraCT number, 2019-004789-17.).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kwatra et al. (2023) studied this question.

synapsesocial.com/papers/69da7db10f32475823a3d5a7 https://doi.org/10.1056/nejmoa2301333

View Full Paper

Ask AI

Bookmark

Share

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis

Ask about this paper

Abstract

Discussion

Cite This Study

Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading